Back to today’s briefing

Story perspectives

FDA Shake-Up Sparks Concerns in Gene Therapy Stocks

6/23/2025

42 6

Summary

Story summary

Nicole Verdun, MD, and Rachael Anatol, PhD, have been placed on administrative leave from the FDA, sparking worries about the agency's stability and causing a dip in cell and gene therapy stocks. This shake-up comes on the heels of a breakthrough CRISPR therapy case, yet FDA leaders remain committed to advancing these innovative treatments through streamlined regulations.

1 of 1

Story summary

Nicole Verdun, MD, and Rachael Anatol, PhD, have been placed on administrative leave from the FDA, sparking worries about the agency's stability and causing a dip in cell and gene therapy stocks. This shake-up comes on the heels of a breakthrough CRISPR therapy case, yet FDA leaders remain committed to advancing these innovative treatments through streamlined regulations.